National Headlines

Listen — EP 225 | Putting it all together … Genetic Tests for Hereditary Cancers with CEO, Alexander Bisignano and Mark McDonough of Phosphorus

By Michael Tetreault, Host of The DocPreneur Podcast and Editor-In-Chief of Concierge Medicine Today and The DPC Journal

Read Recent Story … PhosphorusONE: A genetic test with real value for your health + Phosphorus Receives Approval to Market PhosphorusONE from New York State Department of Health

Part 2 of 2

Today we catch up with two precision medicine industry insiders and insightful business leaders, Alexander Bisignano, the Co-Founder and CEO of Phosphorous and Mark McDonough, Chief Business Officer at Phosphorous.

About Alexander Bisignano, Co-Founder & Chief Executive Officer (CEO) of Phosphorus

Co-Founder & CEO of @Phosphorus, formerly @Recombine. “I believe we can improve healthcare with genomics.” @alxbz

Alexander Bisignano serves as the Chief Executive Officer for Phosphorus. Alex is responsible for long-term direction and development of Phosphorus diagnostic tests, software, and research initiatives. Before Phosphorus, Alex co-founded Recombine, a clinical genetic testing company, which was acquired by CooperSurgical in May of 2016. At Phosphorus and Recombine Alex helped develop novel genotyping and next-generation sequencing platforms for clinical genetics. His work has been presented at the American Society for Reproductive Medicine, the European Society for Human Reproduction and Embryology and a number of other scientific programs. Alex has also appeared on Fox Business and Bloomberg TV as an expert in the genetic testing market. Alex received his B.A. in molecular biology from Princeton University and is a member of Sigma Xi, the Scientific Research Society.

RELATED STORY, Phosphorus: Phosphorus Receives Approval to Market PhosphorusONE from New York State Department of Health

About Mark McDonough, Chief Business Officer, Phosphorus

“As the root of our name Phosphorus implies, we feel we have a responsibility as a “light bearer” of advanced testing to help patients and our client partners every day and make an impact positively on society. We are excited to earn trust and form true partnerships with our hospital, laboratory, clinic, and individual physician clients by delivering high quality results through our software and through our genetics laboratory.”

Mark joined Phosphorus in July 2018 and is responsible for leading the business growth of the organization. He has over 21 years experience in Healthcare Diagnostics. Prior to Phosphorus, Mark was the President and CEO for CombiMatrix (NASDAQ:CBMX) from March 2013 to its sale to Invitae in November, 2017. Prior to CombiMatrix, he held senior Sales and Marketing leadership roles at Pathwork Diagnostics, LabCorp, US LABS, and Ventana Medical Systems (now Roche). Mark served for six years as an Officer in the US Navy prior to joining Ventana. He has a BS degree in Business from Miami University (OH).

In this two-part interview we discuss a variety of complex and insightful precision medicine topics which include:

  • What is Next Generation Sequencing (NGS) and Why Is It Important?
  • What is the clinical value of the Phosphorus One test to the buyer?
  • Why is this an ideal test for a DPC, Exec Health, Concierge Medicine physician to order?
  • What does a sample report look like and what does it tell the patient and doctor?
  • Is the content locked or is it periodically updated and upgraded?
  • What is the cost of the test?
  • Does insurance cover the test?
  • How is the test different than other tests we order (23&Me, OneOme, Healthy screen)?
  • Is there a particular patient demographic that the test is ideally suited for?
  • What is the logistical process? How do I order and get this done?
  • How does a patient use the information garnered from the test in a month? 6 months? A year?

About Phosphorus

Phosphorus’s mission is to improve healthcare for everyone by better understanding and harnessing the power of the human genome. Having built the most comprehensive, high-quality, and cost-effective portfolio of genetic tests, Phosphorus is able to increase access and quality of care in the burgeoning field of genomics. Phosphorus currently provides panel-based, constitutional genetic testing in the specialty areas of Fertility, Cardiology, Lipidology, Oncology, Pharmacology, Ophthalmology, Neurology, and Pediatric/Metabolic disorders, while also offering the most advanced Whole Exome Sequencing test covering the most recent understanding of the human genome. Additionally, Phosphorus provides the ElementsTM software platform to enable any laboratory to easily deploy any of the Phosphorus genetic tests on-premise as a local solution. For more information, please visit our website at www.phosphorus.com.

Links and Resources Discussed In This Interview

LISTEN TO PART 1 HERE …

What can PhosphorusONE tell me about my health?

The genes we sequence on the PhosphorusONE test are grouped into three main categories based on how they can be used to improve your health and well-being:

Genomic Health Reports:

The Genomic Health Reports provided in PhosphorusONE covers the most up to date state of our understanding of severe genetic diseases. We test for 170 well-characterized genetic diseases that collectively impact nearly 4% of the population. The diseases tested span across clinical areas including: Cancers, Heart Disease, Infertility, Vision Loss, Neurology, and Metabolic Disorders.

Wellness Reports:

While not life-threatening, an emerging body of genetic research is helping us to better understand how to optimize for our nutrition, exercise, and sleep habits. The PhosphorusONE test sequences 21 genes covering 16 different wellness reports that collectively may suggest an ideal diet, training regimen, or sleep behavior. Of course, research here is early, and genetics is likely only just a small factor in how well each individual’s habits evolve.

Pharmacogenetic Reports:

The PhosphorusONE test sequences genes that are directly responsible for the metabolic function of 190 different medications. Medications covered on the test include antidepressants, blood thinners, cancer therapies, and pain management drugs. Based on your individual genotype, this test may identify drugs which have lower activity for you, higher activity for you, or in rare cases, drugs that may result in severe or even deadly reactions. In conjunction with input from your physician, this information can be very powerful in managing certain illnesses.

Click Here for an overview of the PhosphorusONE Test compared to others on the market: CLICK HERE

So far, scientists have identified just over 20,000 known genes – or instructions within your DNA for how to make the various proteins in your body. According to the Online Mendelian Inheritance in Man database (OMIM – the leading database tracking diseases related to genes) there are just over 5,000 genes with specific related diseases. (https://www.omim.org/statistics/entry)

The opinions expressed in this article are intended to bring to light recent scientific literature, technology advancements, and ongoing research as it pertains to genetic testing. They are the opinions of our guests. This article is for informational purposes only, and is meant to induce conversation and present educational insight into complex topics. To the extent that medical practitioners may provide input, or have written all or part of this article, this article is not, nor is it meant to be, a substitute for professional medical advice, diagnosis, or treatment.

Categories: National Headlines